Schedule-dependent antitumor effects of 5-fluorouracil combined with sorafenib in hepatocellular carcinoma

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Deng, Lifen ^a   Ren, Zhenggang ^a   Jia, Qingan ^a   Wu, Weizhong ^a   Shen, Hujia ^a   Wang, Yanhong ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

5 fluorouracil; Cell cycle arrest; Hepatocellular carcinoma; Sorafenib

Indexed keywords

CYCLIN D1; FLUOROURACIL; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; RAF PROTEIN; SORAFENIB; STAT3 PROTEIN; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CARCINOMA CELL; CELL CYCLE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; ENZYME INHIBITION; ENZYME REGULATION; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL CARCINOMA; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; CARCINOMA, HEPATOCELLULAR; CELL SURVIVAL; DRUG EFFECTS; FLOW CYTOMETRY; LIVER NEOPLASMS; METABOLISM; TUMOR CELL LINE; WESTERN BLOTTING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DRUG SYNERGISM; FLOW CYTOMETRY; FLUOROURACIL; HUMANS; LIVER NEOPLASMS; NIACINAMIDE; PHENYLUREA COMPOUNDS; SIGNAL TRANSDUCTION;

EID: 84880965812     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-363     Document Type: Article

References (35)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. Ca-A Canc J Clinician 2011, 61:69-90.
2. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012, 379:1245-1255. 10.1016/S0140-6736(11)61347-0, 22353262.
3. Raoul JL, Sangro B, Forner A, Mazzaferro V, Piscaglia F, Bolondi L, Lencioni R. Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: Available evidence and expert opinion on the use of transarterial chemoembolization. Canc Treat Rev 2011, 37:212-220.
4. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, et al. Sorafenib in advanced hepatocellular carcinoma. New England J Med 2008, 359:378-390.
5. Miyaki D, Aikata H, Honda Y, Naeshiro N, Nakahara T, Tanaka M, Nagaoki Y, Kawaoka T, Takaki S, Waki K, et al. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma according to Child-Pugh classification. J Gastroenterol Hepatol 2012, 27:1850-1857. 10.1111/j.1440-1746.2012.07276.x, 23020312.
6. Baek YH, Kim KT, Lee SW, Jeong JS, Park BH, Nam KJ, Cho JH, Kim YH, Roh YH, Lee HS, et al. Efficacy of hepatic arterial infusion chemotherapy in advanced hepatocellular carcinoma. World J Gastroenterol 2012, 18:3426-3434. 10.3748/wjg.v18.i26.3426, 3396196, 22807613.
7. Ocker M, Alajati A, Ganslmayer M, Zopf S, Luders M, Neureiter D, Hahn EG, Schuppan D, Herold C. The histone-deacetylase inhibitor SAHA potentiates proapoptotic effects of 5-fluorouracil and irinotecan in hepatoma cells A-8089-2010. J Canc Res Clin Oncol 2005, 131:385-394.
8. Beeram M, Patnaik A, Rowinsky EK. Raf: A strategic target for therapeutic development against cancer. J Clin Oncol 2005, 23:6771-6790. 10.1200/JCO.2005.08.036, 16170185.
9. Liu L, Cao YC, Chen C, Zhang XM, McNabola A, Wilkie D, Wilhelm S, Lynch M, Carter C. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Canc Res 2006, 66:11851-11858.
10. Tai WT, Cheng AL, Shiau CW, Huang HP, Huang JW, Chen PJ, Chen KF. Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma. J Hepatol 2011, 55:1041-1048. 10.1016/j.jhep.2011.01.047, 21354226.
11. Gu FM, Li QL, Gao Q, Jiang JH, Huang XY, Pan JF, Fan J, Zhou J. Sorafenib inhibits growth and metastasis of hepatocellular carcinoma by blocking STAT3. World J Gastroenterol 2011, 17:3922-3932. 10.3748/wjg.v17.i34.3922, 3198022, 22025881.
12. Petrini I, Lencioni M, Ricasoli M, Iannopollo M, Orlandini C, Oliveri F, Bartolozzi C, Ricci S. Phase II trial of sorafenib in combination with 5-fluorouracil infusion in advanced hepatocellular carcinoma. Canc Chemother Pharmacol 2012, 69:773-780.
13. Zhang Z, Zhou XY, Shen HJ, Wang DX, Wang YH. Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: evidence from an in vitro study. BMC Med 2009, 7.
14. Plastaras JP, Kim S, Liu YY, Dicker DT, Dorsey JF, McDonough J, Cerniglia G, Rajendran RR, Gupta A, Rustgi AK, et al. Cell cycle-dependent and schedule-dependent antitumor effects of sorafenib combined with radiation. Canc Res 2007, 67:9443-9454.
15. Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies B-4111-2009. Pharmacol Rev 2006, 58:621-681. 10.1124/pr.58.3.10, 16968952.
16. Wehler TC, Hamdi S, Maderer A, Graf C, Gockel I, Schmidtmann I, Hainz M, Berger MR, Theobald M, Galle PR, et al. Single-agent therapy with sorafenib or 5-FU is equally effective in human colorectal cancer xenograft-no benefit of combination therapy. Int J Colorectal Dis 2012,
17. Miyake M, Anai S, Fujimoto K, Ohnishi S, Kuwada M, Nakai Y, Inoue T, Tomioka A, Tanaka N, Hirao Y. 5-fluorouracil enhances the antitumor effect of sorafenib and sunitinib in a xenograft model of human renal cell carcinoma. Oncol Lett 2012, 3:1195-1202. 3392575, 22783417.
18. Manov I, Pollak Y, Broneshter R, Iancu TC. Inhibition of doxorubicin-induced autophagy in hepatocellular carcinoma Hep3B cells by sorafenib - the role of extracellular signal-regulated kinase counteraction. FEBS J 2011, 278:3494-3507. 10.1111/j.1742-4658.2011.08271.x, 21790999.
19. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 2007, 1773:1263-1284. 10.1016/j.bbamcr.2006.10.001, 2696318, 17126425.
20. Cagnol S, Chambard JC. ERK and cell death: mechanisms of ERK-induced cell death-apoptosis, autophagy and senescence. FEBS J 2010, 277:2-21. 10.1111/j.1742-4658.2009.07366.x, 19843174.
21. Wilhelm SM, Carter C, Tang LY, Wilkie D, McNabola A, Rong H, Chen C, Zhang XM, Vincent P, McHugh M, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Canc Res 2004, 64:7099-7109.
22. Gao Y, Li HX, Xu LT, Wang P, Xu LY, Cohen L, Yang PY, Gu K, Meng ZQ. Bufalin enhances the anti-proliferative effect of sorafenib on human hepatocellular carcinoma cells through downregulation of ERK. Mol Biol Rep 2012, 39:1683-1689. 10.1007/s11033-011-0908-x, 21617941.
23. Bowman T, Garcia R, Turkson J, Jove R. STATs in oncogenesis. Oncogene 2000, 19:2474-2488. 10.1038/sj.onc.1203527, 10851046.
24. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Canc 2009, 9:798-809.
25. Yu H, Jove R. The STATs of cancer-new molecular targets come of age. Nat Rev Canc 2004, 4:97-105.
26. Yang F, Van Meter TE, Buettner R, Hedvat M, Liang W, Kowolik CM, Mepani N, Mirosevich J, Nam S, Chen MY, et al. Sorafenib inhibits signal transducer and activator of transcription 3 signaling associated with growth arrest and apoptosis of medulloblastomas. Mol Canc Ther 2008, 7:3519-3526.
27. Yang F, Brown C, Buettner R, Hedvat M, Starr R, Scuto A, Schroeder A, Jensen M, Jove R. Sorafenib Induces Growth Arrest and Apoptosis of Human Glioblastoma Cells through the Dephosphorylation of Signal Transducers and Activators of Transcription 3. Mol Canc Ther 2010, 9:953-962.
28. Huang SB, Sinicrope FA. Sorafenib Inhibits STAT3 Activation to Enhance TRAIL-Mediated Apoptosis in Human Pancreatic Cancer Cells. Mol Canc Ther 2010, 9:742-750.
29. Zhao W, Zhang T, Qu BQ, Wu XX, Zhu X, Meng FY, Gu YH, Shu YQ, Shen Y, Sun Y, Xu QA. Sorafenib induces apoptosis in HL60 cells by inhibiting Src kinase-mediated STAT3 phosphorylation. Anti-Canc Drugs 2011, 22:79-88.
30. Chen KF, Tai WT, Liu TH, Huang HP, Lin YC, Shiau CW, Li PK, Chen PJ, Cheng AL. Sorafenib Overcomes TRAIL Resistance of Hepatocellular Carcinoma Cells through the Inhibition of STAT3. Clin Canc Res 2010, 16:5189-5199.
31. Alao JP. The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention. Mol Canc 2007, 6:24.
32. Huynh H, Do PT, Nguyen TH, Chow P, Tan PH, Quach TH, Van T, Soo KC, Tran E. Extracellular signal-regulated kinase induces cyclin D1 and Cdk-2 expression and phosphorylation of retinoblastoma in hepatocellular carcinoma. Int J Oncol 2004, 25:1839-1847.
33. Stacey DW. Cyclin D1 serves as a cell cycle regulatory switch in actively proliferating cells. Curr Opin Cell Biol 2003, 15:158-163. 10.1016/S0955-0674(03)00008-5, 12648671.
34. Blechacz B, Smoot RL, Bronk SF, Werneburg NW, Sirica AE, Gores GJ. Sorafenib Inhibits Signal Transducer and Activator of Transcription-3 Signaling in Cholangiocarcinoma Cells by Activating the Phosphatase Shatterproof 2. Hepatology 2009, 50:1861-1870. 10.1002/hep.23214, 2891152, 19821497.
35. Yoshiba S, Ito D, Nagumo T, Shirota T, Hatori M, Shintani S. Hypoxia induces resistance to 5-fluorouracil in oral cancer cells via G(1) phase cell cycle arrest. Oral Oncol 2009, 45:109-115. 10.1016/j.oraloncology.2008.04.002, 18710819.